Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA. The biotech focuses on trawling the ...
Canadian biotech AbCellera has joined forces with Eli Lilly to co-develop antibody products to prevent and treat COVID-19, the disease caused by the novel SARS-Cov-2 coronavirus. Based in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback